XML 80 R57.htm IDEA: XBRL DOCUMENT
v3.25.2

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 29, 2025 | Jun. 30, 2024 | Jun. 29, 2025 | Jun. 30, 2024
Sales by segment of business |  |  |  |
Sales to customers | $ 23,743 | $ 22,447 | $ 45,636 | $ 43,830
Percent Change (as a percent) | 5.80% |  | 4.10% |
U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 13,544 | 12,569 | $ 25,849 | 24,189
Percent Change (as a percent) | 7.80% |  | 6.90% |
International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 10,199 | 9,878 | $ 19,787 | 19,641
Percent Change (as a percent) | 3.20% |  | 0.70% |
Innovative Medicine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 15,202 | 14,490 | $ 29,075 | 28,052
Percent Change (as a percent) | 4.90% |  | 3.60% |
Innovative Medicine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 9,161 | 8,510 | $ 17,253 | 16,122
Percent Change (as a percent) | 7.60% |  | 7.00% |
Innovative Medicine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 6,041 | 5,980 | $ 11,822 | 11,930
Percent Change (as a percent) | 1.00% |  | (0.90%) |
Innovative Medicine | Oncology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 6,312 | 5,090 | $ 11,990 | 9,904
Percent Change (as a percent) | 24.00% |  | 21.10% |
Innovative Medicine | Oncology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,385 | 2,636 | $ 6,398 | 5,019
Percent Change (as a percent) | 28.40% |  | 27.50% |
Innovative Medicine | Oncology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,928 | 2,455 | $ 5,592 | 4,885
Percent Change (as a percent) | 19.30% |  | 14.50% |
Innovative Medicine | Oncology | CARVYKTI |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 439 | 186 | $ 808 | 343
Innovative Medicine | Oncology | CARVYKTI | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 358 | 167 | 676 | 307
Innovative Medicine | Oncology | CARVYKTI | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 81 | 20 | 132 | 36
Innovative Medicine | Oncology | DARZALEX |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,539 | 2,878 | $ 6,776 | 5,570
Percent Change (as a percent) | 23.00% |  | 21.70% |
Innovative Medicine | Oncology | DARZALEX | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,017 | 1,641 | $ 3,846 | 3,105
Percent Change (as a percent) | 23.00% |  | 23.90% |
Innovative Medicine | Oncology | DARZALEX | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,521 | 1,237 | $ 2,930 | 2,465
Percent Change (as a percent) | 23.00% |  | 18.90% |
Innovative Medicine | Oncology | ERLEADA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 908 | 736 | $ 1,679 | 1,425
Percent Change (as a percent) | 23.40% |  | 17.80% |
Innovative Medicine | Oncology | ERLEADA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 378 | 318 | $ 670 | 603
Percent Change (as a percent) | 18.60% |  | 11.00% |
Innovative Medicine | Oncology | ERLEADA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 530 | 418 | $ 1,009 | 822
Percent Change (as a percent) | 27.00% |  | 22.90% |
Innovative Medicine | Oncology | IMBRUVICA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 735 | 770 | $ 1,444 | 1,554
Percent Change (as a percent) | (4.50%) |  | (7.00%) |
Innovative Medicine | Oncology | IMBRUVICA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 239 | 246 | $ 474 | 511
Percent Change (as a percent) | (2.70%) |  | (7.30%) |
Innovative Medicine | Oncology | IMBRUVICA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 496 | 525 | $ 970 | 1,043
Percent Change (as a percent) | (5.40%) |  | (6.90%) |
Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 179 | 69 | $ 320 | 116
Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 139 | 52 | 252 | 88
Innovative Medicine | Oncology | RYBREVANT + LAZCLUZE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 41 | 17 | 69 | 28
Innovative Medicine | Oncology | TALVEY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 106 | 69 | $ 192 | 127
Percent Change (as a percent) | 55.00% |  | 52.00% |
Innovative Medicine | Oncology | TALVEY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 82 | 59 | $ 150 | 109
Percent Change (as a percent) | 38.00% |  | 36.70% |
Innovative Medicine | Oncology | TALVEY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 24 | 9 | $ 42 | 17
Innovative Medicine | Oncology | Tecvayli |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 166 | 135 | $ 317 | 268
Percent Change (as a percent) | 23.10% |  | 18.20% |
Innovative Medicine | Oncology | Tecvayli | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 114 | 104 | $ 219 | 205
Percent Change (as a percent) | 8.20% |  | 6.60% |
Innovative Medicine | Oncology | Tecvayli | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 52 | 30 | $ 98 | 63
Percent Change (as a percent) | 74.80% |  | 56.00% |
Innovative Medicine | Oncology | ZYTIGA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 145 | 165 | $ 270 | 346
Percent Change (as a percent) | (11.60%) |  | (21.70%) |
Innovative Medicine | Oncology | ZYTIGA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 6 | 11 | $ 13 | 20
Percent Change (as a percent) | (38.90%) |  | (31.90%) |
Innovative Medicine | Oncology | ZYTIGA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 139 | 154 | $ 257 | 326
Percent Change (as a percent) | (9.80%) |  | (21.10%) |
Innovative Medicine | Oncology | Other Oncology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 93 | 83 | $ 182 | 156
Percent Change (as a percent) | 11.70% |  | 16.40% |
Innovative Medicine | Oncology | Other Oncology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 50 | 37 | $ 97 | 70
Percent Change (as a percent) | 36.90% |  | 39.80% |
Innovative Medicine | Oncology | Other Oncology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 42 | 45 | $ 84 | 86
Percent Change (as a percent) | (8.70%) |  | (2.50%) |
Innovative Medicine | Immunology |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 3,993 | 4,722 | $ 7,700 | 8,969
Percent Change (as a percent) | (15.40%) |  | (14.10%) |
Innovative Medicine | Immunology | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,505 | 2,978 | $ 4,701 | 5,431
Percent Change (as a percent) | (15.90%) |  | (13.40%) |
Innovative Medicine | Immunology | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,489 | 1,744 | $ 2,999 | 3,538
Percent Change (as a percent) | (14.60%) |  | (15.20%) |
Innovative Medicine | Immunology | REMICADE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 455 | 393 | $ 922 | 827
Percent Change (as a percent) | 15.90% |  | 11.50% |
Innovative Medicine | Immunology | REMICADE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 283 | 231 | $ 597 | 497
Percent Change (as a percent) | 22.50% |  | 20.10% |
Innovative Medicine | Immunology | REMICADE | U.S. Exports |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 34 | 35 | $ 44 | 62
Percent Change (as a percent) | (2.60%) |  | (28.70%) |
Innovative Medicine | Immunology | REMICADE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 138 | 127 | $ 281 | 268
Percent Change (as a percent) | 8.60% |  | 4.80% |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 690 | 537 | $ 1,349 | 1,091
Percent Change (as a percent) | 28.60% |  | 23.70% |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 305 | 267 | $ 597 | 521
Percent Change (as a percent) | 14.00% |  | 14.40% |
Innovative Medicine | Immunology | SIMPONI / SIMPONI ARIA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 387 | 270 | $ 753 | 569
Percent Change (as a percent) | 43.10% |  | 32.20% |
Innovative Medicine | Immunology | STELARA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,653 | 2,885 | $ 3,278 | 5,336
Percent Change (as a percent) | (42.70%) |  | (38.60%) |
Innovative Medicine | Immunology | STELARA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,078 | 1,855 | $ 2,059 | 3,251
Percent Change (as a percent) | (41.90%) |  | (36.70%) |
Innovative Medicine | Immunology | STELARA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 575 | 1,030 | $ 1,219 | 2,085
Percent Change (as a percent) | (44.20%) |  | (41.50%) |
Innovative Medicine | Immunology | TREMFYA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,186 | 906 | $ 2,142 | 1,714
Percent Change (as a percent) | 31.00% |  | 25.00% |
Innovative Medicine | Immunology | TREMFYA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 796 | 589 | $ 1,395 | 1,098
Percent Change (as a percent) | 35.20% |  | 27.10% |
Innovative Medicine | Immunology | TREMFYA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 391 | 317 | $ 747 | 616
Percent Change (as a percent) | 23.20% |  | 21.20% |
Innovative Medicine | Immunology | OTHER IMMUNOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 8 | 2 | $ 9 | 2
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 8 | 2 | 9 | 2
Innovative Medicine | Immunology | OTHER IMMUNOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
Innovative Medicine | Infectious Diseases |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 803 | 965 | $ 1,605 | 1,786
Percent Change (as a percent) | (16.80%) |  | (10.10%) |
Innovative Medicine | Infectious Diseases | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 320 | 334 | $ 635 | 658
Percent Change (as a percent) | (4.30%) |  | (3.60%) |
Innovative Medicine | Infectious Diseases | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 484 | 631 | $ 971 | 1,128
Percent Change (as a percent) | (23.40%) |  | (13.90%) |
Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 360 | 297 | $ 718 | 620
Percent Change (as a percent) | 21.60% |  | 15.90% |
Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 6 | 8 | $ 14 | 16
Percent Change (as a percent) | (25.40%) |  | (13.60%) |
Innovative Medicine | Infectious Diseases | EDURANT/rilpivirine | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 354 | 288 | $ 704 | 603
Percent Change (as a percent) | 23.00% |  | 16.70% |
Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 396 | 438 | $ 799 | 856
Percent Change (as a percent) | (9.40%) |  | (6.60%) |
Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 312 | 321 | $ 617 | 635
Percent Change (as a percent) | (3.00%) |  | (2.90%) |
Innovative Medicine | Infectious Diseases | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 85 | 117 | $ 183 | 221
Percent Change (as a percent) | (27.00%) |  | (17.20%) |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 47 | 233 | $ 88 | 311
Percent Change (as a percent) | (79.80%) |  | (71.70%) |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2 | 5 | $ 4 | 7
Percent Change (as a percent) | (51.80%) |  | (37.40%) |
Innovative Medicine | Infectious Diseases | OTHER INFECTIOUS DISEASES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 45 | 227 | $ 84 | 304
Percent Change (as a percent) | (80.50%) |  | (72.50%) |
Innovative Medicine | Neuroscience |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,051 | 1,782 | $ 3,698 | 3,585
Percent Change (as a percent) | 15.10% |  | 3.20% |
Innovative Medicine | Neuroscience | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,377 | 1,102 | $ 2,345 | 2,156
Percent Change (as a percent) | 24.90% |  | 8.70% |
Innovative Medicine | Neuroscience | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 674 | 679 | $ 1,353 | 1,428
Percent Change (as a percent) | (0.80%) |  | (5.20%) |
Innovative Medicine | Neuroscience | CAPLYTA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 211 | 0 | $ 211 | 0
Innovative Medicine | Neuroscience | CAPLYTA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 211 | 0 | 211 | 0
Innovative Medicine | Neuroscience | CAPLYTA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 164 | 163 | $ 312 | 340
Percent Change (as a percent) | 0.20% |  | (8.30%) |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 24 | 34 | $ 62 | 75
Percent Change (as a percent) | (27.70%) |  | (16.60%) |
Innovative Medicine | Neuroscience | CONCERTA / methylphenidate | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 139 | 129 | $ 249 | 265
Percent Change (as a percent) | 7.50% |  | (6.00%) |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 992 | 1,054 | $ 1,895 | 2,110
Percent Change (as a percent) | (5.90%) |  | (10.20%) |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 732 | 784 | $ 1,357 | 1,549
Percent Change (as a percent) | (6.70%) |  | (12.40%) |
Innovative Medicine | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 260 | 269 | $ 537 | 561
Percent Change (as a percent) | (3.50%) |  | (4.20%) |
Innovative Medicine | Neuroscience | SPRAVATO |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 414 | 271 | $ 734 | 496
Percent Change (as a percent) | 53.30% |  | 48.10% |
Innovative Medicine | Neuroscience | SPRAVATO | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 366 | 226 | $ 642 | 417
Percent Change (as a percent) | 61.10% |  | 53.70% |
Innovative Medicine | Neuroscience | SPRAVATO | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 50 | 44 | $ 93 | 78
Percent Change (as a percent) | 12.80% |  | 18.10% |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 270 | 294 | $ 547 | 639
Percent Change (as a percent) | (8.40%) |  | (14.40%) |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 45 | 57 | $ 73 | 115
Percent Change (as a percent) | (23.50%) |  | (37.00%) |
Innovative Medicine | Neuroscience | OTHER NEUROSCIENCE | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 226 | 237 | $ 474 | 524
Percent Change (as a percent) | (4.70%) |  | (9.50%) |
Innovative Medicine | Pulmonary Hypertension |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,113 | 1,039 | $ 2,138 | 2,088
Percent Change (as a percent) | 7.10% |  | 2.40% |
Innovative Medicine | Pulmonary Hypertension | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 799 | 743 | $ 1,543 | 1,509
Percent Change (as a percent) | 7.60% |  | 2.30% |
Innovative Medicine | Pulmonary Hypertension | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 314 | 296 | $ 595 | 579
Percent Change (as a percent) | 5.80% |  | 2.60% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 582 | 548 | $ 1,104 | 1,072
Percent Change (as a percent) | 6.40% |  | 3.00% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 403 | 376 | $ 766 | 732
Percent Change (as a percent) | 6.90% |  | 4.60% |
Innovative Medicine | Pulmonary Hypertension | OPSUMIT/OPSYNVI | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 180 | 171 | $ 339 | 340
Percent Change (as a percent) | 5.40% |  | (0.30%) |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 476 | 426 | $ 927 | 894
Percent Change (as a percent) | 11.70% |  | 3.70% |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 382 | 349 | $ 747 | 741
Percent Change (as a percent) | 9.40% |  | 0.80% |
Innovative Medicine | Pulmonary Hypertension | UPTRAVI | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 94 | 76 | $ 180 | 152
Percent Change (as a percent) | 22.40% |  | 17.90% |
Innovative Medicine | Pulmonary Hypertension | Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 55 | 67 | $ 107 | 123
Percent Change (as a percent) | (16.90%) |  | (12.50%) |
Innovative Medicine | Pulmonary Hypertension | Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 16 | 17 | $ 31 | 35
Percent Change (as a percent) | (12.40%) |  | (12.60%) |
Innovative Medicine | Pulmonary Hypertension | Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 40 | 49 | $ 77 | 88
Percent Change (as a percent) | (18.50%) |  | (12.40%) |
Innovative Medicine | Cardiovascular / Metabolism / Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 930 | 892 | $ 1,943 | 1,721
Percent Change (as a percent) | 4.20% |  | 12.90% |
Innovative Medicine | Cardiovascular / Metabolism / Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 776 | 717 | $ 1,631 | 1,348
Percent Change (as a percent) | 8.20% |  | 21.00% |
Innovative Medicine | Cardiovascular / Metabolism / Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 154 | 176 | $ 312 | 373
Percent Change (as a percent) | (12.30%) |  | (16.20%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 309 | 305 | $ 632 | 616
Percent Change (as a percent) | 1.40% |  | 2.70% |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 155 | 129 | $ 320 | 243
Percent Change (as a percent) | 20.00% |  | 31.60% |
Innovative Medicine | Cardiovascular / Metabolism / Other | Other | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 154 | 176 | $ 312 | 373
Percent Change (as a percent) | (12.30%) |  | (16.20%) |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 621 | 587 | $ 1,311 | 1,105
Percent Change (as a percent) | 5.60% |  | 18.60% |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 621 | 587 | $ 1,311 | 1,105
Percent Change (as a percent) | 5.60% |  | 18.60% |
Innovative Medicine | Cardiovascular / Metabolism / Other | XARELTO | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 0 | 0 | $ 0 | 0
Percent Change (as a percent) | 0.00% |  | 0.00% |
MEDTECH |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 8,541 | 7,957 | $ 16,561 | 15,778
Percent Change (as a percent) | 7.30% |  | 5.00% |
MEDTECH | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,383 | 4,059 | $ 8,596 | 8,067
Percent Change (as a percent) | 8.00% |  | 6.60% |
MEDTECH | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 4,158 | 3,898 | $ 7,965 | 7,711
Percent Change (as a percent) | 6.70% |  | 3.30% |
MEDTECH | Cardiovascular |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,313 | 1,873 | $ 4,416 | 3,679
Percent Change (as a percent) | 23.50% |  | 20.00% |
MEDTECH | Cardiovascular | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,364 | 1,119 | $ 2,625 | 2,144
Percent Change (as a percent) | 21.90% |  | 22.40% |
MEDTECH | Cardiovascular | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 948 | 753 | $ 1,790 | 1,534
Percent Change (as a percent) | 25.90% |  | 16.70% |
MEDTECH | ELECTROPHYSIOLOGY |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,468 | 1,323 | $ 2,791 | 2,667
Percent Change (as a percent) | 11.00% |  | 4.70% |
MEDTECH | ELECTROPHYSIOLOGY | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 741 | 705 | $ 1,425 | 1,397
Percent Change (as a percent) | 5.10% |  | 2.00% |
MEDTECH | ELECTROPHYSIOLOGY | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 728 | 618 | $ 1,366 | 1,270
Percent Change (as a percent) | 17.80% |  | 7.60% |
MEDTECH | ABIOMED |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 448 | 379 | $ 868 | 750
Percent Change (as a percent) | 18.20% |  | 15.70% |
MEDTECH | ABIOMED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 360 | 309 | $ 699 | 612
Percent Change (as a percent) | 16.60% |  | 14.20% |
MEDTECH | ABIOMED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 89 | 72 | $ 170 | 139
Percent Change (as a percent) | 25.00% |  | 22.40% |
MEDTECH | Shockwave |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 292 | 77 | $ 550 | 77
MEDTECH | Shockwave | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 233 | 77 | 439 | 77
MEDTECH | Shockwave | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | 58 | 0 | 110 | 0
MEDTECH | Other Cardiovascular |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 104 | 93 | $ 207 | 185
Percent Change (as a percent) | 10.80% |  | 11.70% |
MEDTECH | Other Cardiovascular | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 31 | 29 | $ 63 | 59
Percent Change (as a percent) | 5.40% |  | 6.30% |
MEDTECH | Other Cardiovascular | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 72 | 64 | $ 144 | 126
Percent Change (as a percent) | 13.40% |  | 14.20% |
MEDTECH | Orthopaedics |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,305 | 2,312 | $ 4,546 | 4,652
Percent Change (as a percent) | (0.30%) |  | (2.30%) |
MEDTECH | Orthopaedics | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,420 | 1,422 | $ 2,804 | 2,870
Percent Change (as a percent) | (0.20%) |  | (2.30%) |
MEDTECH | Orthopaedics | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 885 | 890 | $ 1,742 | 1,782
Percent Change (as a percent) | (0.50%) |  | (2.20%) |
MEDTECH | Orthopaedics | HIPS |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 421 | 417 | $ 830 | 839
Percent Change (as a percent) | 1.00% |  | (1.10%) |
MEDTECH | Orthopaedics | HIPS | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 271 | 265 | $ 534 | 535
Percent Change (as a percent) | 2.10% |  | (0.20%) |
MEDTECH | Orthopaedics | HIPS | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 150 | 152 | $ 296 | 304
Percent Change (as a percent) | (1.00%) |  | (2.50%) |
MEDTECH | Orthopaedics | KNEES |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 389 | 394 | $ 778 | 795
Percent Change (as a percent) | (1.10%) |  | (2.00%) |
MEDTECH | Orthopaedics | KNEES | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 226 | 230 | $ 457 | 472
Percent Change (as a percent) | (1.90%) |  | (3.10%) |
MEDTECH | Orthopaedics | KNEES | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 164 | 163 | $ 322 | 323
Percent Change (as a percent) | 0.00% |  | (0.50%) |
MEDTECH | Orthopaedics | TRAUMA |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 768 | 759 | $ 1,540 | 1,524
Percent Change (as a percent) | 1.20% |  | 1.10% |
MEDTECH | Orthopaedics | TRAUMA | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 501 | 498 | $ 1,003 | 1,002
Percent Change (as a percent) | 0.70% |  | 0.10% |
MEDTECH | Orthopaedics | TRAUMA | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 267 | 260 | $ 537 | 521
Percent Change (as a percent) | 2.20% |  | 2.90% |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 727 | 743 | $ 1,398 | 1,495
Percent Change (as a percent) | (2.10%) |  | (6.50%) |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 422 | 430 | $ 810 | 862
Percent Change (as a percent) | (1.70%) |  | (6.00%) |
MEDTECH | Orthopaedics | SPINE, SPORTS & OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 305 | 314 | $ 588 | 634
Percent Change (as a percent) | (2.70%) |  | (7.20%) |
MEDTECH | Surgery |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 2,555 | 2,488 | $ 4,951 | 4,904
Percent Change (as a percent) | 2.70% |  | 1.00% |
MEDTECH | Surgery | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,043 | 995 | $ 2,045 | 1,982
Percent Change (as a percent) | 4.80% |  | 3.20% |
MEDTECH | Surgery | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,512 | 1,493 | $ 2,906 | 2,922
Percent Change (as a percent) | 1.30% |  | (0.50%) |
MEDTECH | Surgery | ADVANCED |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,164 | 1,141 | $ 2,237 | 2,228
Percent Change (as a percent) | 2.00% |  | 0.40% |
MEDTECH | Surgery | ADVANCED | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 477 | 466 | $ 934 | 912
Percent Change (as a percent) | 2.20% |  | 2.40% |
MEDTECH | Surgery | ADVANCED | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 687 | 675 | $ 1,303 | 1,316
Percent Change (as a percent) | 1.90% |  | (1.00%) |
MEDTECH | Surgery | GENERAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,391 | 1,346 | $ 2,714 | 2,676
Percent Change (as a percent) | 3.30% |  | 1.40% |
MEDTECH | Surgery | GENERAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 567 | 528 | $ 1,111 | 1,070
Percent Change (as a percent) | 7.20% |  | 3.80% |
MEDTECH | Surgery | GENERAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 825 | 818 | $ 1,603 | 1,606
Percent Change (as a percent) | 0.90% |  | (0.10%) |
MEDTECH | Vision |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 1,369 | 1,285 | $ 2,648 | 2,543
Percent Change (as a percent) | 6.50% |  | 4.10% |
MEDTECH | Vision | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 557 | 523 | $ 1,123 | 1,070
Percent Change (as a percent) | 6.50% |  | 4.90% |
MEDTECH | Vision | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 813 | 763 | $ 1,526 | 1,473
Percent Change (as a percent) | 6.50% |  | 3.60% |
MEDTECH | Vision | CONTACT LENSES / OTHER |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 965 | 918 | $ 1,884 | 1,828
Percent Change (as a percent) | 5.10% |  | 3.10% |
MEDTECH | Vision | CONTACT LENSES / OTHER | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 429 | 409 | $ 881 | 847
Percent Change (as a percent) | 4.80% |  | 3.90% |
MEDTECH | Vision | CONTACT LENSES / OTHER | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 536 | 509 | $ 1,003 | 981
Percent Change (as a percent) | 5.40% |  | 2.30% |
MEDTECH | Vision | SURGICAL |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 403 | 367 | $ 764 | 715
Percent Change (as a percent) | 9.90% |  | 6.90% |
MEDTECH | Vision | SURGICAL | U.S. |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 128 | 113 | $ 242 | 223
Percent Change (as a percent) | 12.60% |  | 8.50% |
MEDTECH | Vision | SURGICAL | International |  |  |  |
Sales by segment of business |  |  |  |
Sales to customers | $ 277 | $ 254 | $ 523 | $ 492
Percent Change (as a percent) | 8.80% |  | 6.20% |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_InnovativeMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CARVYKTIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ERLEADAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RYBREVANTLAZCLUZEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TALVEYMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TecvayliMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CAPLYTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPRAVATOMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITOPSYNVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ElectrophysiologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_AbiomedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ShockwaveMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OtherCardiovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |